Cardiovasc Prev Pharmacother.  2023 Apr;5(2):54-60. 10.36011/cpp.2023.5.e5.

Fabry disease screening in young patients with acute ischemic stroke in Korea

• Choi Y
• Ok T
• Lee KY

• KMID: 2541759
• DOI: http://doi.org/10.36011/cpp.2023.5.e5

Abstract

Background
Fabry disease is an X-linked lysosomal storage disorder that results from a mutation in the α-galactosidase A (GLA) gene. It shows multiple organ involvement, including cerebrovascular disease. Since Fabry disease has a prevalence of approximately 4% in young patients with cryptogenic stroke, screening for this condition is recommended for young stroke patients. This study aimed to investigate the prevalence of Fabry disease in young acute ischemic stroke patients in Korea, the distribution of GLA gene mutations, and the subtypes of ischemic stroke.
Methods
This study included 211 young patients with acute ischemic stroke or transient ischemic attack. To screen for Fabry disease, α-galactosidase A (α-Gal A) enzyme activity was measured and DNA sequencing analysis of the GLA gene was performed.
Results
None of the patients exhibited low α-Gal A enzyme activity or had a pathogenic GLA mutation, but 18 nonpathogenic GLA gene variants were detected, including c.-10C>T in 16 patients, c.-33C>T in one patient, and c.196G>C in one patient. The mean α-Gal A enzyme activity in 14 male patients with the c.-10C>T variant was 5.17±1.19, which was significantly lower than that of male patients with the normal genotype (7.47±3.48, P<0.05). The distribution of stroke subtypes in patients with GLA gene polymorphisms was not significantly different from that in patients with a normal genotype.
Conclusions
This study demonstrates that Fabry disease is rare in young patients with ischemic stroke or transient ischemic attack in Korea, and we suggest that routine screening for Fabry disease may not be necessary for ischemic stroke patients.

Keyword

alpha-Galactosidase; Fabry disease; Ischemic stroke

Reference

1. Kolodny E, Fellgiebel A, Hilz MJ, Sims K, Caruso P, Phan TG, et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke. 2015; 46:302–13.

2. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008; 105:2812–7.

3. Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005; 366:1794–6.

4. Schiffmann R, Fuller M, Clarke LA, Aerts JM. Is it Fabry disease? Genet Med. 2016; 18:1181–5.

5. Vardarli I, Rischpler C, Herrmann K, Weidemann F. Diagnosis and screening of patients with Fabry disease. Ther Clin Risk Manag. 2020; 16:551–8.

6. Linthorst GE, Bouwman MG, Wijburg FA, Aerts JM, Poorthuis BJ, Hollak CE. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet. 2010; 47:217–22.

7. Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, et al. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke. 2013; 44:340–9.

8. Nagamatsu K, Sekijima Y, Nakamura K, Nakamura K, Hattori K, Ota M, et al. Prevalence of Fabry disease and GLA c.196G>C variant in Japanese stroke patients. J Hum Genet. 2017; 62:665–70.

9. Song X, Xue S, Zhao J, Wu J. Screening for Fabry’s disease in young patients with ischemic stroke in a Chinese population. Int J Neurosci. 2017; 127:350–5.

10. Fancellu L, Borsini W, Romani I, Pirisi A, Deiana GA, Sechi E, et al. Exploratory screening for Fabry’s disease in young adults with cerebrovascular disorders in northern Sardinia. BMC Neurol. 2015; 15:256.

11. Baptista MV, Ferreira S, Pinho-E-Melo T, Carvalho M, Cruz VT, Carmona C, et al. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study: screening genetic conditions in Portuguese young stroke patients. Stroke. 2010; 41:431–6.

12. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993; 24:35–41.

13. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17:405–24.

14. Tomek A, Petra R, Paulasova Schwabova J, Olserova A, Skorna M, Nevsimalova M, et al. Nationwide screening for Fabry disease in unselected stroke patients. PLoS One. 2021; 16:e0260601.

15. Gilchrist M, Casanova F, Tyrrell JS, Cannon S, Wood AR, Fife N, et al. Prevalence of Fabry disease-causing variants in the UK Biobank. J Med Genet. 2023; 60:391–6.

16. Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, et al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Circ Cardiovasc Genet. 2009; 2:450–6.

17. Sakuraba H, Tsukimura T, Togawa T, Tanaka T, Ohtsuka T, Sato A, et al. Fabry disease in a Japanese population-molecular and biochemical characteristics. Mol Genet Metab Rep. 2018; 17:73–9.

18. Yoshitama T, Nakao S, Takenaka T, Teraguchi H, Sasaki T, Kodama C, et al. Molecular genetic, biochemical, and clinical studies in three families with cardiac Fabry’s disease. Am J Cardiol. 2001; 87:71–5.

19. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003; 64:801–7.

20. Cho BH, Lee KY. Various clinical manifestations in a heterozygous Fabry disease family: from asymptomatic to acute ischemic stroke with intracranial cerebral artery stenosis. J Clin Neurol. 2020; 16:505–6.

21. Nakamura K, Sekijima Y, Nakamura K, Hattori K, Nagamatsu K, Shimizu Y, et al. p.E66Q mutation in the GLA gene is associated with a high risk of cerebral small-vessel occlusion in elderly Japanese males. Eur J Neurol. 2014; 21:49–56.

22. Togawa T, Tsukimura T, Kodama T, Tanaka T, Kawashima I, Saito S, et al. Fabry disease: biochemical, pathological and structural studies of the α-galactosidase A with E66Q amino acid substitution. Mol Genet Metab. 2012; 105:615–20.

23. Lee BH, Heo SH, Kim GH, Park JY, Kim WS, Kang DH, et al. Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet. 2010; 55:512–7.

24. Gervas-Arruga J, Cebolla JJ, Irun P, Perez-Lopez J, Plaza L, Roche JC, et al. Increased glycolipid storage produced by the inheritance of a complex intronic haplotype in the α-galactosidase A (GLA) gene. BMC Genet. 2015; 16:109.

25. Zeevi DA, Hakam-Spector E, Herskovitz Y, Beeri R, Elstein D, Altarescu G. An intronic haplotype in α galactosidase A is associated with reduced mRNA expression in males with cryptogenic stroke. Gene. 2014; 549:275–9.

26. Oliveira JP, Ferreira S, Barcelo J, Gaspar P, Carvalho F, Sa Miranda MC, et al. Effect of single-nucleotide polymorphisms of the 5’ untranslated region of the human α-galactosidase gene on enzyme activity, and their frequencies in Portuguese caucasians. J Inherit Metab Dis. 2008; 31 Suppl 2:S247–53.

27. Varela P, Mastroianni Kirsztajn G, Motta FL, Martin RP, Turaca LT, Ferrer HL, et al. Correlation between GLA variants and alpha-Galactosidase A profile in dried blood spot: an observational study in Brazilian patients. Orphanet J Rare Dis. 2020; 15:30.

28. Balendran S, Oliva P, Sansen S, Mechtler TP, Streubel B, Cobos PN, et al. Diagnostic strategy for females suspected of Fabry disease. Clin Genet. 2020; 97:655–60.